34.41  -1.38 (-3.86%)		12-26 16:00
Open: 35.7 High: 35.98 Volume: 653,421		Pre. Close: 35.79 Low: 34.37 Market Cap: 2,940(M)

Short term
Mid term
Targets	6-month :	42.52	1-year :	49.67
Resists	First :	36.4	Second :	42.52
Pivot price	34.33
Supports	First :	31.06	Second :	27.76
MAs	MA(5) :	35.15	MA(20) :	33.9
	MA(100) :	27.09	MA(250) :	0
MACD	MACD :	1.5	Signal :	1.7
%K %D	K(14,3) :	74.5	D(3) :	82.9
RSI	RSI(14): 57.2
52-week	High :	36.4	Low :	11.26

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ LQDA ] has closed below upper band by 47.8%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	36.03 - 36.21	36.21 - 36.36
Low:	33.96 - 34.15	34.15 - 34.3
Close:	34.15 - 34.44	34.44 - 34.68

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Fri, 26 Dec 2025
Liquidia (LQDA) Receives Reiterated 'Buy' Rating from BTIG Analy - GuruFocus

Fri, 26 Dec 2025
Liquidia (NASDAQ:LQDA) Receives "Buy" Rating from BTIG Research - MarketBeat

Thu, 25 Dec 2025
Assessing Liquidia (LQDA) Valuation After Bullish Analyst Reaffirmations and YUTREPIA Patent Uncertainty - simplywall.st

Wed, 24 Dec 2025
February 2026 Options Now Available For Liquidia (LQDA) - Nasdaq

Tue, 23 Dec 2025
How Liquidia’s Reaffirmed Analyst Support and Revenue Momentum Will Impact Liquidia (LQDA) Investors - Sahm

Mon, 22 Dec 2025
Liquidia (NASDAQ:LQDA) Sets New 52-Week High - Here's Why - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	87 (M)
Held by Insiders	6.065e+007 (%)
Held by Institutions	13.1 (%)
Shares Short	17,550 (K)
Shares Short P.Month	0 (K)

EPS	-1.0604e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-179.3 %
Operating Margin	3.2 %
Return on Assets (ttm)	-25.4 %
Return on Equity (ttm)	-187.3 %
Qtrly Rev. Growth	1 %
Gross Profit (p.s.)	253.54
Sales Per Share	1.44208e+008
EBITDA (p.s.)	1.28479e+008
Qtrly Earnings Growth	-1.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-101 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	66.08

Dividend	0
Forward Dividend	1.408e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.